Related Experiment Video
Updated: Jun 15, 2026
miRNA Expression Analyses in Prostate Cancer Clinical Tissues
Published on: September 8, 2015
Analysis of NSAID-activated gene 1 expression in prostate cancer
Takashi Kawahara1, Hitoshi Ishiguro, Koji Hoshino
1Department of Urology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Abstract:
Nonsteroidal anti-inflammatory drugs (NSAIDs) induce expression of NSAID-activated gene 1 (NAG-1). NAG-1 expression in prostate cancer has previously been detected by microarray and immunohistochemical analyses. We examined the mRNA expression of NAG-1 by quantitative real-time polymerase chain reaction using 51 human prostate cancer tissue specimens. The level of NAG-1 expression was higher in prostate cancer than in normal prostate tissues (p = 0.025). The level of NAG-1 expression was also significantly higher in well-differentiated prostate cancer than in moderately (p = 0.04) and poorly differentiated adenocarcinomas (p = 0.03). These data suggest that NAG-1 may be a new biomarker for evaluating the grade of malignancy in prostate cancer.
Insights
Nonsteroidal anti-inflammatory drugs (NSAIDs) increase NSAID-activated gene 1 (NAG-1) expression. Higher NAG-1 levels in prostate cancer suggest it may indicate malignancy grade.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Nonsteroidal anti-inflammatory drugs (NSAIDs) are known to induce NSAID-activated gene 1 (NAG-1).
- Previous studies detected NAG-1 expression in prostate cancer via microarray and immunohistochemistry.
Purpose of the Study:
- To quantify messenger RNA (mRNA) expression of NAG-1 in human prostate cancer tissues.
- To investigate the correlation between NAG-1 expression levels and prostate cancer differentiation.
- To explore NAG-1 as a potential biomarker for prostate cancer malignancy grade.
Main Methods:
- Quantitative real-time polymerase chain reaction (qPCR) was employed.
- Analysis was performed on 51 human prostate cancer tissue specimens.
- NAG-1 mRNA levels were compared between cancerous and normal prostate tissues, and across different grades of differentiation.
Main Results:
- NAG-1 mRNA expression was significantly higher in prostate cancer tissues compared to normal prostate tissues (p = 0.025).
- Significantly elevated NAG-1 expression was observed in well-differentiated prostate cancer relative to moderately (p = 0.04) and poorly differentiated (p = 0.03) adenocarcinomas.
Conclusions:
- NAG-1 expression is upregulated in prostate cancer.
- NAG-1 levels correlate with the degree of prostate cancer differentiation.
- NAG-1 shows potential as a novel biomarker for assessing prostate cancer malignancy grade.
